

Darryl See, M.D. – Keynote Speaker

Speaking at Convention 2001, Dr. Darryl See, a research scientist who has published over 30 peer-reviewed journal articles on chronic viral illnesses and immunological disorders, addressed the audience with some incredibly powerful information regarding Transfer Factor. With a medical degree from the University of California at Irvin and a board certification in both Internal Medicine and Infectious Disease, Dr. See's studies on Transfer Factor add a vast array of credibility to the unprecedented impact of this exclusive product.

Dr. See conducted the independent in vitro study that tested hundreds of natural products for their ability to raise natural killer cell activity, including Transfer Factor and Transfer Factor Plus. Natural killer cells work on the front-line of our immune system, destroying harmful cells through direct contact.

As a result of that study, Dr. See concluded that 4Life Transfer Factor and Transfer Factor Plus far outperformed the competition. Transfer Factor raised Natural Killer (NK) Cell Activity by 102 percent and Transfer Factor Plus raised activity by 248 percent.

Recently, Dr. See conducted another study, this time in late stage cancer patients with a regime that included Transfer Factor Plus. He presented the results of this study at the 4Life National Convention. Dr. See again tested NK cell function, as well as the Tumor Necrosis Factor (TNF) in patients. Tumor Necrosis Factor alpha is a cytokine produced primarily by monocytes and macrophages. Also, It is found in synovial cells. It is a substance that has antitumor effects.



Darryl See, M.D.

INCREASED TUMOR NECROSIS FACTOR ALPHA AND NK CELL FUNCTION USING AN INTEGRATIVE APPROACH IN LATE STAGE CANCERS

PATIENT DEMOGRAPHICS	PATIENT REGIME INCLUDED	RESULTS AFTER SIX MONTHS
Twenty patients Average age: 49.3 All stage 4 cancers 12 males, 8 females Prognosis from physician: 3.7 months to live	Transfer Factor Plus, Beta Glucans, soy extract, digestive enzymes, vegetarian, low-sugar diet, hyperthermia and more.	Average Tumor Necrosis Factor alpha (TNF) increased from 12.4 to 1287.5 Average increase in NK cell function: 6.4 to 27.6

Sixteen out of the 20 patients studied are in remission, either improving or in stable condition. Dr. See stated that Transfer Factor Plus was an essential part of the regimen. When they removed it, the patients' progress began to slow down. Commenting about the Transfer Factor Plus, Dr. See said, "Nothing has ever come close to TF Plus in efficacy ... I think everyone in the world should be on this product."

Note: These results are from Dr. See's independent study. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease.

Reference:
<http://health.excite.com/content/article/2946.428>